Thromb Haemost 2011; 105(02): 274-278
DOI: 10.1160/TH10-07-0460
Blood Coagulation, Fibrinolysis and Cellular Haemostasis
Schattauer GmbH

Cardiovascular risk assessment in haemophilia patients

Sara Biere-Rafi
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Manuel A. Baarslag
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Marjolein Peters
2   Department of Pediatric Hematology, Emma Children’s Hospital AMC, Amsterdam, The Netherlands
,
Marieke J. H. A Kruip
3   Department of Hematology, Erasmus Medical Center, Rotterdam, The Netherlands
,
Roderik A. Kraaijenhagen
4   NDDO Institute for Prevention and Early Diagnostics, Amsterdam, The Netherlands
,
Martin Den Heijer
5   Department of Endocrinology, Radboud University Medical Center, Nijmegen, The Netherlands
,
Harry R. Büller
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
,
Pieter W. Kamphuisen
1   Department of Vascular Medicine, Academic Medical Center, Amsterdam, the Netherlands
› Author Affiliations
Further Information

Publication History

Received: 19 July 2010

Accepted after major revision: 22 October 2010

Publication Date:
25 November 2017 (online)

Preview

Summary

Haemophilia patients have a reduced cardiovascular mortality, which may be the result of a lifelong deficiency of factor VIII or IX. On the other hand, the prevalence of risk factors may differ in these chronically ill patients compared to the general population. The prevalence of risk factors and expected risk of cardiovascular disease was compared in haemophilia patients and healthy controls. In adult haemophilia A and B patients, body mass index, blood pressure, cholesterol levels and fasting glucose levels were measured and compared to healthy age-matched males. The expected risk of mortality due to cardiovascular disease was calculated using a European risk prediction algorithm (SCORE). A total of 100 haemophilia A and B patients and 200 healthy controls were analysed. The mean age of the patients was 47 years (range 18–83). The number of haemophiliacs with hyperglycaemia (24%) and hypertension (51%) was higher than in the controls (p-values 0.001 and 0.03, respectively). The mean low-density lipoprotein (LDL) cholesterol level in cases was lower than the controls (3.02 mM (0.69–6.57) and 3.60 mM (1.68–5.95), respectively, p < 0.001). Fewer cases had increased LDL levels (p=0.045). No difference was found in the 10-year cardiovascular mortality risk >10% between cases and controls (12% and 7%, respectively, p = 0.18). The prevalence of risk factors and expected risk of cardiovascular disease in haemophilia patients is comparable to the general population. This strengthens the hypothesis that hypocoagulability may reduce cardiovascular mortality in haemophilia patients.